We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LIPIODOL (Guerbet Australia Pty Ltd)
Product name
LIPIODOL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 working days (255)
Active ingredients
iodised oil
Registration type
EOI
Indication
In interventional radiology
LIPIODOL (solution for injection) is now also indicated as an imaging agent for visualisation and localisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma (HCC) at intermediate stage in adults (see section 4.3 -Contraindications and Section 4.4 Special Warnings and Precautions for Use).